Saama Launches AI-Driven Data Platform
Suite of AI-enhanced SaaS solutions address many functions within clinical development.
Saama, a provider of AI- and ML-based solutions for clinical development and commercialization, announced its unified platform of SaaS-based products. By applying AI and advanced analytics to clinical development processes, Saama’s platform aims to eliminate manual, resource-intensive activities.
Saama uses more than 90 AI models built for life sciences, trained on over 300 million data points, which are embedded into the Saama platform. The platform includes the following solutions:
* Data Hub – to centralize and standardize clinical, operational, financial, and more data in a single location.
* Operational Insights – to provide a holistic view of trial operations to all team members and with visualizations of data including EDC, CTMS, and eTMF data.
* Patient Insights – to centralize and visualize patient data in a single location, and applies AI to patient data that can be used to predict patient behavior and track progress.
* Source to Submission (S2S) – automates the SDTM transformation process with AI/ML to simplify regulatory submissions.
* Smart Data Quality (SDQ) – automates data cleaning, review, and reconciliation processes for data managers to reduce query review.
Source: Saama Launches Industry’s First AI-driven Data Platform to Accelerate Clinical Development, June 20, 2023, BUSINESS WIRE.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
WCG Meets Enrollment 24 Months Early for Top 5 Pharma’s Decentralized Trial
October 31st 2024A sponsor needed to get their Phase II dermatology study enrollment back on track. The study was underway for 11 months across 32 sites globally with only 20 subjects enrolled to date. With WCG support, enrollment was concluded 24 months ahead of schedule.
